Skip Ribbon Commands
Skip to main content

UCHealth Home

:

Clinical Trials: RTOG 1008: A Randomized Phase II Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors

 


RTOG 1008: A Randomized Phase II Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors


Trial Focus

Head and Neck Cancers

Objective

         This is a clinical trial of cisplatin that will be administered by IV which is standard of care and radiation therapy that will be administered standard of care.

IRB Protocol #

13-2078

Trial Status

Archived

Principle Investigator

DAVID RABEN

Sponsor

RTOG

Contact

MONICA ROBISCHON at (720) 848-0661 or MONICA.ROBISCHON@UCDENVER.EDU

Location

University of Colorado Hospital University of Colorado Hospital

Eligibility and Other Participant Information


What To Expect : A screening period to determine eligibility. A treatment period that can last up to 6 to 7 weeks. A follow up period will consist of clinic visits for for 3 to 6 months for the first 4 years and then phone contact afterwards. // Eligibility criteria include but are not limited to 18 years or older with salivary gland tumors.Eligibility criteria include but are not limited to 18 years or older with salivary gland tumors.